{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=89",
    "query": {
      "intervention": "Dose Level -1",
      "page": 89
    },
    "page_size": 10
  },
  "pagination": {
    "page": 89,
    "page_size": 10,
    "total_count": 29142,
    "total_pages": 2915,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=90&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=88&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T00:04:39.265Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06005740",
      "title": "A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "TORL-4-500",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TORL Biotherapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-12-04",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005740"
    },
    {
      "nct_id": "NCT05333289",
      "title": "A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Influenza"
      ],
      "interventions": [
        {
          "name": "mRNA-1030",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1020",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 572,
      "start_date": "2022-04-06",
      "completion_date": "2022-11-22",
      "has_results": true,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05333289"
    },
    {
      "nct_id": "NCT03710889",
      "title": "Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal",
        "Osteoporosis",
        "Osteoporosis Vertebral",
        "Osteoporosis Risk",
        "Osteoporosis Fracture",
        "Osteoporosis Localized to Spine",
        "Osteoporosis, Age-Related",
        "Osteoporosis Senile",
        "Osteoporosis of Vertebrae"
      ],
      "interventions": [
        {
          "name": "Abaloparatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radius Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 85 Years · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2018-09-20",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 4,
      "location_summary": "Golden, Colorado • Gainesville, Georgia • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03710889"
    },
    {
      "nct_id": "NCT02540668",
      "title": "A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lanabecestat",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2015-09-30",
      "completion_date": "2016-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-11-04",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02540668"
    },
    {
      "nct_id": "NCT06619990",
      "title": "Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "XmAb942",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 270,
      "start_date": "2024-10-10",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 31,
      "location_summary": "Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619990"
    },
    {
      "nct_id": "NCT02601560",
      "title": "To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "MEDI6012",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 48,
      "start_date": "2015-12-03",
      "completion_date": "2016-11-03",
      "has_results": true,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 8,
      "location_summary": "Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601560"
    },
    {
      "nct_id": "NCT03362723",
      "title": "A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Idasanutlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2017-11-27",
      "completion_date": "2019-06-11",
      "has_results": false,
      "last_update_posted_date": "2019-06-19",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03362723"
    },
    {
      "nct_id": "NCT02849080",
      "title": "Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "semaglutide",
          "type": "DRUG"
        },
        {
          "name": "sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2016-09-20",
      "completion_date": "2019-03-27",
      "has_results": true,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 37,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Lancaster, California + 33 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849080"
    },
    {
      "nct_id": "NCT02215096",
      "title": "Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK2636771",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 37,
      "start_date": "2014-11-13",
      "completion_date": "2019-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215096"
    },
    {
      "nct_id": "NCT00570479",
      "title": "Prophylactic Anecortave Acetate in Patients With a Retisert Implant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveitis, Posterior",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "anecortave acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "10 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2006-09",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-05",
      "last_synced_at": "2026-11-21T00:04:39.265Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570479"
    }
  ]
}